TREATS Act
- Bill Number
- S. 3048
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-10-23: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-06-17T11:03:25Z
AI-Generated Summary
Purpose
The TREATS Act (S. 3048) aims to expand access to substance use disorder (SUD) treatment by allowing telehealth—remote medical consultations via technology—for prescribing certain controlled substances. This addresses barriers to care, such as geographic distance or limited in-person services, while maintaining federal regulations on controlled substances.
Key Provisions
- Amendment to In-Person Requirement: Modifies the Controlled Substances Act to permit a single telehealth evaluation instead of a required in-person medical evaluation for prescribing controlled substances in schedules III, IV, or V that the Food and Drug Administration (FDA) has approved specifically for treating SUD. (Schedules refer to categories of drugs regulated by the Drug Enforcement Administration (DEA) based on abuse potential; III, IV, and V are lower-risk than I or II.)
- Definition of Telehealth Evaluation: Defines this as a remote medical assessment conducted by a qualified practitioner (not a pharmacist) using telecommunications systems that enable real-time, two-way audio-only or audio-video communication. It must comply with federal and state laws and aligns with standards in the Social Security Act for Medicare telehealth services.
Significant Changes to Existing Law
- Under current law (Controlled Substances Act, Section 309(e)(2)), prescribers must conduct at least one in-person evaluation before issuing telehealth prescriptions for controlled substances. The bill replaces this with an option for a telehealth evaluation specifically for FDA-approved SUD medications in schedules III through V, broadening flexibility without eliminating all in-person requirements for other prescriptions.
- Introduces a clear legal definition for telehealth evaluations, ensuring consistency with broader federal telehealth guidelines established during the COVID-19 pandemic.
Potential Impacts
- On Citizens: Increases access to SUD treatment for individuals in rural, underserved, or mobility-limited areas, potentially reducing overdose risks and improving recovery rates by making medications like buprenorphine (for opioid use disorder) easier to prescribe remotely.
- On Government Agencies: The DEA will need to update enforcement and registration processes to accommodate telehealth for SUD prescriptions, while the FDA's role in drug approvals remains unchanged. This could strain resources for monitoring compliance but streamline federal support for telehealth expansions.
- On International Relations: Minimal direct impact, though it may indirectly support U.S. global health initiatives on addiction by demonstrating commitment to innovative treatment access.
Main Stakeholders Affected
- Patients with SUD: Primary beneficiaries, gaining easier entry to evidence-based treatments without travel barriers.
- Healthcare Providers: Physicians and practitioners can use telehealth more readily for SUD care, reducing administrative hurdles but requiring adherence to new remote protocols.
- Telehealth Providers and Platforms: Companies offering remote consultation services will see expanded opportunities in regulated prescribing.
- Regulatory Agencies: DEA (oversees controlled substances), FDA (drug approvals), and state health boards (enforce local telehealth laws) must adapt guidelines and oversight.
- Insurers and Payers: Including Medicare and private plans, potentially facing increased claims for telehealth SUD services but benefiting from lower overall treatment costs.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens the framework for telehealth under federal drug laws by codifying pandemic-era flexibilities, reducing ambiguity in enforcement. It preserves patient privacy through existing telecommunications standards but may prompt future litigation if states impose conflicting rules.
- Constitutional: No apparent challenges; aligns with Congress's authority to regulate interstate commerce and public health under the Commerce Clause.
- Political: Bipartisan support (introduced by 20 senators from both parties) signals broad consensus on addressing the opioid crisis. It builds on temporary COVID-19 waivers, potentially influencing future permanent telehealth reforms, and highlights a shift toward technology-enabled healthcare equity without overhauling broader drug scheduling.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (22)
Sen. Whitehouse, Sheldon [D-RI], Sen. Warner, Mark R. [D-VA], Sen. Tillis, Thomas [R-NC], Sen. Kaine, Tim [D-VA], Sen. Sullivan, Dan [R-AK], Sen. Luján, Ben Ray [D-NM], Sen. Cortez Masto, Catherine [D-NV], Sen. Merkley, Jeff [D-OR], Sen. Hickenlooper, John W. [D-CO], Sen. Wyden, Ron [D-OR], Sen. Heinrich, Martin [D-NM], Sen. Klobuchar, Amy [D-MN], Sen. Fetterman, John [D-PA], Sen. Kelly, Mark [D-AZ], Sen. Markey, Edward J. [D-MA], Sen. Gallego, Ruben [D-AZ], Sen. Warren, Elizabeth [D-MA], Sen. Welch, Peter [D-VT], Sen. Booker, Cory A. [D-NJ], Sen. Bennet, Michael F. [D-CO], Sen. Ossoff, Jon [D-GA], Sen. Daines, Steve [R-MT]
Recent Actions
- 2025-10-23: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-10-23: Introduced in Senate
Bill Versions
- Telehealth Response for E-prescribing Addiction Therapy Services Act — issued 2025-10-23 — PDF (3 pages)